MANAGEMENT OF A 71-YEAR-OLD PATIENT WITH COPD EXACERBATION, BRONCHIECTASIS, AND PSEUDOMONAS AERUGINOSA COLONIZATION – CASE REPORT
Abstract
Chronic Obstructive Pulmonary Disease (COPD) frequently coexists with non-cystic fibrosis bronchiectasis (NCFB), creating a clinical overlap associated with persistent airway infection, frequent exacerbations, and accelerated functional decline. Among pathogens, Pseudomonas aeruginosa colonization confers a particularly unfavorable prognosis. We report a 71-year-old male admitted with severe dyspnea and productive cough with purulent sputum. Baseline arterial blood gases confirmed type II (hypercapnic) respiratory failure. Chest radiography excluded new focal consolidations. Bronchoscopy revealed abundant purulent secretions; bronchoaspirate culture grew P. aeruginosa susceptible to meropenem and colistin. In line with current practice and GOLD 2025 principles for acute exacerbation management, the patient received targeted antimicrobial therapy, short-acting bronchodilators, a short course of systemic corticosteroids, long-term oxygen therapy (LTOT), and daily airway clearance. The hospital course was favorable with PaCO₂ decreasing and marked symptomatic improvement; at three months he re-presented with recurrent purulent cough and again had P. aeruginosa in culture, prompting extended inhaled colistin and consideration of prophylactic macrolide therapy. This case underscores practical aspects of COPD–bronchiectasis overlap, highlights decision points around eradication strategies for P. aeruginosa, and illustrates the role of individualized, multidisciplinary follow-up aligned with GOLD 2025 and ERS guidance.
References
Global Initiative for Chronic Obstructive Lung Disease. (2025). Global strategy for the diagnosis, management, and prevention of COPD (2025 report) (Version 1.0, November 15, 2024). GOLD.
Polverino, E., Goeminne, P. C., McDonnell, M. J., Aliberti, S., Marshall, S. E., Loebinger, M. R., … Chalmers, J. D. (2017). European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal, 50(3), 1700629. https://doi.org/10.1183/13993003.00629-2017
British Thoracic Society Bronchiectasis Guideline Group. (2019). British Thoracic Society guideline for bronchiectasis in adults. Thorax, 74(Suppl 1), 1–69. https://doi.org/10.1136/thoraxjnl-2018-212463
Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A., Criner, G. J., … Make, B. J. (2011). Azithromycin for prevention of exacerbations of COPD. New England Journal of Medicine, 365(8), 689–698. https://doi.org/10.1056/NEJMoa1104623
Murphy, P. B., Rehal, S., Arbane, G., Bourke, S., Calverley, P. M., Crook, A. M., … Polkey, M. I. (2017). Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: The HOT-HMV randomized clinical trial. JAMA, 317(21), 2177–2186. https://doi.org/10.1001/jama.2017.4451
Choi, H., Chalmers, J. D., Kwon, N., … Chalmers, J. D. (2024). Bronchiectasis management in adults: State of the art and future directions. European Respiratory Journal, 63(6), 2400518. https://doi.org/10.1183/13993003.00518-2024
Halpin, D. M. G., et al. (2025). What’s new in the 2025 GOLD report. NPJ Primary Care Respiratory Medicine, 35, Article 27. https://doi.org/10.1038/s41533-025-00392-0
LaFon, D. C., & Thomsen, M. (2024). Bronchiectasis–chronic obstructive pulmonary disease overlap: An evolving syndrome. American Journal of Respiratory and Critical Care Medicine, 209(7), 791–793. https://doi.org/10.1164/rccm.202402-0314ED
Hurst, J. R., Elborn, J. S., & De Soyza, A. (2015). COPD–bronchiectasis overlap syndrome. European Respiratory Journal, 45(2), 310–313. https://doi.org/10.1183/09031936.00140014
Copyright (c) 2025 Wiktor Golus, Katarzyna Andrzejewska, Paweł Edyko, Bartosz Golis, Zuzanna Przybyła, Hubert Woźniak, Anna Gęsińska, Krystian Czyżykowski, Alicja Babula, Helena Szelka

This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.

